Waters (Waters) Debt-to-Asset : 0.53 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Waters Debt-to-Asset?

Waters's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $78 Mil. Waters's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2,364 Mil. Waters's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $4,627 Mil. Waters's debt to asset for the quarter that ended in Dec. 2023 was 0.53.

Waters Debt-to-Asset Historical Data

The historical data trend for Waters's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waters Debt-to-Asset Chart

Waters Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.69

0.51

0.52

0.51

0.53

Waters Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.51	0.47	0.60	0.58	0.53

Competitive Comparison of Waters's Debt-to-Asset

For the Diagnostics & Research subindustry, Waters's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Waters's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Waters's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Waters's Debt-to-Asset falls into.

Waters Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Waters's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(77.825	+	2364.439)	/	4626.854
	=	0.53

Waters's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(77.825	+	2364.439)	/	4626.854
	=	0.53

Waters (NYSE:WAT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Waters Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Waters's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Waters (Waters) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Waters Corp (NYSE:WAT) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

WAT:Mexico WAZ:Germany

Address

34 Maple Street, Milford, MA, USA, 01757

Website

https://www.waters.com

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.

Executives

Christopher A Kuebler	director	210 CARNEGIE CENTER, PRINCETON NJ 08540
Richard H Fearon	director	1239 GERBING ROAD, AMELIA ISLAND FL 32034
Edward Conard	director
Daniel J. Brennan	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Mark P Vergnano	director	1007 MARKET STREET, WILMINGTON DE 19898
Gary E Hendrickson	director	1101 THIRD STREET SOUTH, MINNEAPOLIS MN 55415
John M Ballbach	director
Linda Baddour	director	PRA INTERNATIONAL, 12120 SUNSET HILLS ROAD, SUITE 600, RESTON VA 20190
Michael J Berendt	director
Thomas P Salice	director
Wei Jiang	director	34 MAPLE STREET, MILFORD MA 01757
Amol Chaubal	officer: SVP and Chief Financial Office	113 HARTWELL AVE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421
Jianqing Bennett	officer: SVP TA Instruments Division	34 MAPLE STREET, MILFORD MA 01757
Joann A Reed	director	C/O AMERICAN TOWER CORP, 116 HUNTINGTON AVENUE, BOSTON MA 02116
Belinda Hyde	officer: SVP, Global Human Resources	13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277